DOT-EPT-Header


Targeting the histone methylome as a therapeutic strategy has quickly captured the interest of developers worldwide, due to the genetic and expression abnormalities of histone methyltransferases and demethylases displayed in a variety of human cancers, as well as the chemically tractable nature of these modifying enzymes. Adding to the more established series of histone methyltransferase targets, histone demethylases of both JmjC and CoREST domains have also advanced into clinical development and are now showing favorable clinical outcomes. Notably, increased interest in developing inhibitors against arginine methyltranslferase enzymes has substantially deepened the possibilities of regulating chromatin environments via histone methylation, and thereby expanding this already robust target space.

Cambridge Healthtech Institute will once again convene leaders in epigenetic drug development to further our understanding of the role aberrant histone methylation plays in disease, to evaluate lead and clinical compounds by developers, and to introduce novel chemical matter for further development.

Preliminary Agenda


MECHANISMS REGULATING GENE EXPRESSION AND TUMORIGENESIS

Targeting Arginine Methyltransferases in Cancer Therapy

Robert A. Baiocchi, M.D., Ph.D., Associate Professor, Division of Hematology, Department of Internal Medicine, The Ohio State University

JARID1/KDM5 Demethylases as Cancer Targets

Qin Yan, Ph.D., Associate Professor, Department of Pathology, Yale School of Medicine

Critical Roles of Non-Histone Protein Methylation in Human Tumorigenesis

Ryuji Hamamoto, Ph.D., Associate Professor, Hematology & Oncology, The University of Chicago


DISCOVERY AND DEVELOPMENT OF NOVEL BIOACTIVE CHEMICAL MATTEr

Exploring Preclinical Stage Programs at Epizyme

Jesse Smith, Ph.D., Executive Director, Biological Sciences, Epizyme

Chemical Tractability of Protein Methyltransferases: Lessons Learned from Protein Structures and Screening Campaigns

Matthieu Schapira, Ph.D., Principal Investigator, Computational Chemistry, Structural Genomics Consortium; Associate Professor, Department of Pharmacology & Toxicology, University of Toronto

A Multifaceted Strategy for Discovering Chemical Probes of Histone Methyltransferases

Anqi Ma, Ph.D., Senior Research Scientist, Jian Jin Laboratory, Medicinal Chemistry, Chemical Biology & Drug Discovery, Icahn School of Medicine at Mount Sinai


THERAPEUTIC OPPORTUNITIES TARGETING THE HISTONE METHYLOME

FEATURED PRESENATION: Targeting the Histone Demethylome

Udo Oppermann, Ph.D., Professor, Molecular Biology; Director, Molecular Laboratory Sciences, Botnar Research Centre; Principal Investigator, Epigenetics and Metabolism, Structural Genomics Consortium, University of Oxford

Inhibition of LSD1 as a Therapeutic Strategy for the Treatment of AML and SCLC

Ryan Kruger, Ph.D., Director, Discovery Biology, GlaxoSmithKline

Development of Histone Demethylase Inhibitors for Oncological and Neurodegenerative Disease

Tamara Maes, Ph.D., Co-Founder, Vice President & CSO, Oryzon Genomics



For questions or suggestions about the meeting, please contact:
Kip Harry
Conference Director
Cambridge Healthtech Institute
T: (+1) 781-972-5454
E: kharry@healthtech.com 

For sponsorship and exhibit sales information including sponsored podium presentations, contact:
Jon Stroup
Sr. Business Development Manager
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com 

DOT Hub Icon

2014 Discovery on Target Brochure  


IPR_Micrombiome 


2014 BROCHURE 

 PREMIER SPONSORS 

Cellecta 

Molecular Sensing 

Rosa Drug Development Advisors
 

VIEW ALL SPONSORS 

VIEW MEDIA PARTNERS 


SPONSORSHIPS & EXHIBITS 

The exhibit hall was sold out in 2014, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2015, contact:

Jon Stroup
Sr. Business Development Manager
781-972-5483
jstroup@healthtech.com 


Westin Boston Waterfront

HOTEL & TRAVEL 

Westin Boston Waterfront
425 Summer Street
Boston, MA 02210
617.426.2000